Editor, OncLive
Courtney Flaherty started working for OncLive in 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media and email strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: [email protected]
Roger Li, MD, discusses how the synergistic mechanism of pembrolizumab plus CG0070 could address unmet needs in BCG-unresponsive NMIBC, safety and efficacy data for the combination from the CORE-001 trial, and how those data support planned research efforts for CG0070 in this space.
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, discusses key safety and efficacy data from the EPCORE NHL-1 trial that may serve to support the approval of epcoritamab in patients with relapsed or refractory large B-cell lymphoma, and highlighted ongoing research efforts seeking to further move the needle forward in this disease.
Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer.
Benjamin H. Lowentritt, MD, FACS, highlights key findings from the retrospective study of second-generation ARSI use in patients with metastatic castration-sensitive prostate cancer treated in clinic and discusses several directions for future analyses of real-world outcomes in prostate cancer.
Jayesh Desai, MBBS, FRACP, reports prior phase 1 data on the use of divarasib monotherapy in KRAS G12C–mutated CRC and early efficacy, safety, and presents pharmacokinetic data from the use of divarasib plus cetuximab from a phase 1 trial.
Thomas M. Habermann, MD, expands on previous data that supported the initial accelerated approval of ibrutinib in marginal zone lymphoma and mantle cell lymphoma, phase 3 data leading to the agent’s voluntary withdrawal, and investigations of ibrutinib and other BTK inhibitors that could significantly change the treatment landscape in mantle cell lymphoma and marginal zone lymphoma.
Proof of mechanism and safety has been established for the first-in-class bisialidase and Fc fusion protein E-602 in advanced solid tumors, supporting its continued investigation and viability of harnessing glycan-mediated immune regulation as a novel therapeutic approach in this population.
Alexander Putnam Cole, MD, discusses the importance of investigating racial and ethnic disparities in prostate cancer outcomes, key data from a comparison of cancer-specific survival according to race and treatment modality, and how these results could better inform efforts to improve access to, and quality of, patient care in this disease.
The frontline combination of ribociclib and letrozole significantly prolonged overall survival over letrozole alone in a subset of patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy, according to data from an exploratory analysis of the phase 3 MONALEESA-2 trial.
Administration of trilaciclib followed by sacituzumab govitecan showed early signals of efficacy and may reduce the incidence of adverse effects in heavily pretreated patients with unresectable locally advanced or metastatic triple-negative breast cancer, according to preliminary results from a phase 2 study.
Ahmed O. Kaseb, MD, discusses how the previous approval of atezolizumab and bevacizumab in hepatocellular carcinoma provided the impetus for the IMBrave050 study, how data from this study could support the regimen’s approval in the adjuvant setting, and how this approval could substantially improve the treatment landscape for early-stage disease.
Shilpa Gupta, MD, discussed the significance of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer, updated data on the use of avelumab maintenance therapy following first-line chemotherapy in this population, and how this research could better inform patient-provider conversations about this option in the clinic.
Attaya Suvannasankha, MD, discusses the unique mechanism of action of REGN5459, the early efficacy and safety of the immunotherapy in heavily pretreated patients with relapsed/refractory multiple myeloma, and opportunities for further exploration.
The TKI anlotinib plus the PARP inhibitor niraparib continued to provide overall survival benefit with an acceptable safety profile when given to patients with platinum-resistant recurrent ovarian cancer.
Aristotelis Bamias, MD, discusses the efficacy and safety data from the final OS analysis of the IMvigor130 trial and emphasizes the clinical implications of this research in metastatic urothelial cancer.
Bertrand F. Tombal, MD, PhD, explains how data on the clinically relevant drug-drug interactions and TRAEs with darolutamide, docetaxel and ADT support previously reported efficacy data from the ARASENS trial, and presents lingering questions and caveats from this trial that should be addressed through continued research.
Administration of aumolertinib until intracranial oligoprogression, followed by salvage stereotactic radiation therapy, produced central nervous system responses with acceptable tolerability in patients with intracranial oligometastatic EGFR-mutant non–small cell lung cancer.
Ryan J. Sullivan, MD, discusses previous research on tebentafusp in uveal melanoma that led to the inception of the IMCgp100-202 trial and clinical implications for data confirming the predictive value of circulating tumor DNA levels.
Balazs Halmos, MD, discusses factors to consider when selecting a biomarker assay for patients with non–small cell lung cancer, emphasizes the importance of secondary testing, provides recommendations for the treatment of patients with co-mutations, and highlights ongoing or future areas of interest for research within lung cancer.
Karen L. Reckamp, MD, MS, discusses the rationale for evaluating patients with early-stage NSCLC who received adjuvant atezolizumab as part of the LCMC3 study and explains the significance and limitations of data from a retrospective analysis.
Matthew Galsky, MD, highlights updates in metastatic urothelial cancer treatment, as well as the evolution of PARP inhibitors and the optimal use of intensified triplet therapy in prostate cancer.
Bradley A. McGregor, MD, discusses the clinical significance of the updated COSMIC-021 data, how these findings support the continued investigation of IO/TKI combinations in non–clear cell renal cell carcinoma, and other efforts underway to better care for patients with varying histological subtypes of the disease.
Andrea Necchi, MD, discusses the efficacy and safety data reported from the FIDES-02 study, explains the clinical relevance of these data despite the trial’s negative result, and highlights several other influential studies presented at the 2023 Genitourinary Cancers Symposium.
AZD3759 elicited clinical responses and had an acceptable toxicity profile when administered at a dose of 200 mg twice daily in patients with untreated EGFR-mutant non–small cell lung cancer and central nervous system metastases, according to data from the phase 2 TRUMP trial.
Samer A. Srour, MB ChB, MS, explains the unique construction of ALLO-316, the potential for ALLO-316 to address an unmet need in patients with clear cell renal cell carcinoma, and how early data from the TRAVERSE study support the continued investigation of ALLO-316 in patients with CD70-expressing tumors.
Ursula A. Matulonis highlights previous data from the phase 3 ENGOT-OV16/NOVA trial initial readout and subsequent preplanned overall survival analysis, discusses new findings from the final analysis, and emphasizes how these data clarify some of the study’s limitations and reinforce the importance of adhering to the adjusted FDA label for niraparib in recurrent ovarian cancer.
Brian M. Slomovitz, MD, discusses key efficacy and safety data seen with ribociclib and letrozole in the GOG 3026 trial and planned efforts to identify associated biomarkers and pursue FDA approval for the combination in advanced, recurrent low-grade serous ovarian cancer.
Joshua G. Cohen, MD, FACOG, FACS, expands on the role of PARP inhibitors in the recurrent and up-front settings in ovarian cancer, and the clinical significance of the RUBY and NY-GY018 trials in endometrial cancer.
Joshua K. Sabari, MD, shares how the unique pharmacokinetics and mechanism of action for LY3537982 supported its investigation in the LOXO-RAS- 20001 study, findings presented at AACR, and how this research could address unmet needs in patients with KRAS G12C–mutant solid tumors.
Jane Lowe Meisel, MD, discusses previously reported data from the ELAINE-1 and ELAINE-2 trials, their significance within the ESR1-mutant, ER-positive, HER2-negative breast cancer treatment paradigm, and the purpose of the ongoing ELAINE-3 trial.
